Adamed Sp. Z O.o.

Adamed Pharma S.a.

Bartlomiej Zerek

Sebastian Dominik Pawlak

Jerzy Szczepan Pieczykolan

Krzysztof Kazimierz Lemke

Sebastian Pawlak

The fusion protein, especially recombinant, comprising domain (a) which is a functional fragment of soluble hTRAIL protein sequence beginning with an amino acid at a position not lower than hTRAIL95 or a sequence having at least 70% homology thereto; and domain (b) which is a sequence of pro-apoptotic effector peptide, wherein the sequence of domain (b) is attached at C-terminus and/or N-terminus of domain (a). The fusion protein has anticancer activity. The nucleotide sequence coding the fusion protein, expression vector and host cell for the preparation of the fusion protein, and the use of the fusion protein for treating cancer diseases.

Growing community of inventors

Dabrowa, Poland

Bartlomiej Zerek